Kymera Discloses New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Platform and Discovery Updates, and Outlines 5-year Vision and Goals at 2021 R&D Day
December 16, 2021 07:00 ET
|
Kymera Therapeutics, Inc.
Multiple Ascending Dose (MAD) data from KT-474 Phase 1 trial demonstrates near complete IRAK4 degradation in PBMC and skin, robust ex vivo inhibition of multiple disease-relevant cytokines, and...
Kymera Therapeutics Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor Malignancies at 63rd American Society of Hematology (ASH) Annual Meeting
December 13, 2021 08:00 ET
|
Kymera Therapeutics, Inc.
Two presentations demonstrated Kymera’s STAT3 degraders can reduce STAT3 expression, modify STAT3-dependent signaling, and suppress the growth of tumors in multiple preclinical models of lymphoma and...
Kymera Therapeutics Strengthens Leadership Team with the Appointment of Vijay Sabesan as Senior Vice President, Technical Operations
December 06, 2021 08:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413
November 30, 2021 08:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Therapeutics to Host Virtual R&D Day on December 16, 2021
November 17, 2021 08:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
November 12, 2021 07:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel...
Kymera Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Business Update
November 10, 2021 07:00 ET
|
Kymera Therapeutics, Inc.
Proof-of-mechanism and proof-of-biology established for first-in-class, oral IRAK4 degrader, KT-474, in Single Ascending Dose portion of Phase 1 healthy volunteer trial with up to 96% degradation in...
Kymera Therapeutics to Present New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting and the 63rd American Society of Hematology (ASH) Annual Meeting
November 04, 2021 08:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel...
Kymera Therapeutics to Participate in Upcoming Fourth Quarter Investor Conferences
November 01, 2021 08:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Therapeutics Presents Positive Data Demonstrating Robust IRAK4 Degradation and First Proof-of-Biology with Inhibition of Cytokine Induction from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers
October 27, 2021 07:00 ET
|
Kymera Therapeutics, Inc.
Mean IRAK4 degradation of up to 96% in PBMC and up to 97% inhibition of ex vivo induction of multiple proinflammatory cytokines observed, suggesting potential for broad anti-inflammatory effect ...